Alnylam Pharmaceuticals competitors and similar companiesClear all

Alnylam Pharmaceuticals's competitors and similar companies include Reata Pharmaceuticals, Celyad, Sorrento Therapeutics, Moderna, CureVac, Regulus Therapeutics, Sarepta Therapeutics and Ionis Pharmaceuticals.

	Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.	Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.	Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.	Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.	Moderna Moderna is a biotechnology company that develops therapeutics and vaccines.	CureVac CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology.	Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.	Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Founding Date	Founding Date 2002	Founding Date 2002	Founding Date 2007	Founding Date 2006	Founding Date 2010	Founding Date 2000	Founding Date 2007	Founding Date 1980	Founding Date 1989
Type	Type Public	Type Public	Type Public	Type Public	Type Public	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development genetics	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more	Locations Plano, US HQ Irving, US Plano, US	Locations Mont-Saint-Guibert, BE HQ New York, US	Locations San Diego, US HQ San Diego, US	Locations Cambridge, US HQ Norwood, US	Locations Tübingen, DE HQ Frankfurt Am Main, DE Tübingen, DE Boston, US	Locations San Diego, US HQ	Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US	Locations Carlsbad, US HQ
Employees	Employees 1,32324% increase	Employees 22079% increase	Employees 95	Employees 31019% decrease	Employees 2,700108% increase	Employees 4004% increase	Employees 2462% decrease	Employees 8403% decrease	Employees 7577% decrease
Valuation ($)	Valuation ($) 27.7 b	Valuation ($) 1.4 b	Valuation ($) 28.3 m	Valuation ($) 309.4 m	Valuation ($) 78.3 b	Valuation ($) 1.5 b	Valuation ($) 223.3 m	Valuation ($) 10.7 b	Valuation ($) 5.6 b
Twitter followers	Twitter followers 16 k	Twitter followers 1.3 k	Twitter followers 2.4 k	Twitter followers N/A	Twitter followers 151 k	Twitter followers 10	Twitter followers 808	Twitter followers 4.6 k	Twitter followers 4.3 k
Number of tweets (last 30 days)	Number of tweets (last 30 days) 27	Number of tweets (last 30 days) 6	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) 30	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) N/A	Number of tweets (last 30 days) 7	Number of tweets (last 30 days) 8
Average likes per tweet (last 30 days)	Average likes per tweet (last 30 days) 9.1	Average likes per tweet (last 30 days) 2.3	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) 33.3	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) N/A	Average likes per tweet (last 30 days) 10.1	Average likes per tweet (last 30 days) 6.4
Percentage of tweets with engagement (last 30 days)	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) 100%	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) N/A	Percentage of tweets with engagement (last 30 days) 71.43%	Percentage of tweets with engagement (last 30 days) 100%
Alexa Website Rank	Alexa Website Rank 376993	Alexa Website Rank 267230	Alexa Website Rank 460272	Alexa Website Rank 412753	Alexa Website Rank 288967	Alexa Website Rank 457967	Alexa Website Rank 181560	Alexa Website Rank 448530	Alexa Website Rank 333062
Employee Rating	Employee Rating 4.2	Employee Rating 3.6	Employee Rating 3.5	Employee Rating 3.4	Employee Rating 3.7	Employee Rating 3.2	Employee Rating 2.8	Employee Rating 4.1	Employee Rating 3.6
Financial
Revenue (est.)	Revenue (est.) $844.3m (FY, 2021)	Revenue (est.) $11.5m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) $52.9m (FY, 2021)	Revenue (est.) $18.5b (FY, 2021)	Revenue (est.) €12.6m (FY, 2018)	Revenue (est.) N/A	Revenue (est.) $701.9m (FY, 2021)	Revenue (est.) $810.5m (FY, 2021)
Cost of goods	Cost of goods $115m (FY, 2021)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $2.6b (FY, 2021)	Cost of goods €22.3m (FY, 2018)	Cost of goods N/A	Cost of goods $97m (FY, 2021)	Cost of goods $10.8m (FY, 2021)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €5.8m (FY, 2021)	Gross profit N/A	Gross profit $15.9b (FY, 2021)	Gross profit (€9.8m) (FY, 2018)	Gross profit N/A	Gross profit $604.8m (FY, 2021)	Gross profit N/A
Net income	Net income ($852.8m) (FY, 2021)	Net income ($297.4m) (FY, 2021)	Net income (€26.5m) (FY, 2021)	Net income ($429.1m) (FY, 2021)	Net income $12.2b (FY, 2021)	Net income (€74.6m) (FY, 2018)	Net income ($27.8m) (FY, 2021)	Net income ($418.8m) (FY, 2021)	Net income ($28.6m) (FY, 2021)
Operating ⚠
Patent Applications	Patent Applications N/A	Patent Applications N/A	Patent Applications N/A	Patent Applications N/A	Patent Applications 430 (FY, 2021)	Patent Applications 500 (Mar, 2020)	Patent Applications N/A	Patent Applications N/A	Patent Applications N/A
Patents (US)	Patents (US) N/A	Patents (US) N/A	Patents (US) N/A	Patents (US) N/A	Patents (US) 170 (FY, 2021)	Patents (US) N/A	Patents (US) N/A	Patents (US) N/A	Patents (US) 161 (Jun, 2021)
Patents Issued	Patents Issued N/A	Patents Issued 240 (FY, 2016)	Patents Issued N/A	Patents Issued N/A	Patents Issued 270 (FY, 2020)	Patents Issued 233 (May, 2020)	Patents Issued 300 (FY, 2016)	Patents Issued N/A	Patents Issued N/A
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 2 (FY, 2016)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 3 (May, 2020)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 6 (FY, 2020)
Phase II Trials Products	Phase II Trials Products N/A	Phase II Trials Products 4 (FY, 2016)	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 24 (FY, 2020)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 1 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 6 (FY, 2020)
Funding
Total funding raised	Total funding raised $ 1.5b	Total funding raised $ 468.9m	Total funding raised N/A	Total funding raised $ 42.6m	Total funding raised $ 1.8b	Total funding raised $ 1.1b	Total funding raised $ 10m	Total funding raised N/A	Total funding raised N/A